6-Azauridine sars

Combined with fast diagnostic tools to recognize 2019-nCoA infection, antivirals may provide a more appropriate therapy. As the largest class of small molecule-based antivirals for chemotherapy of virus infections, nucleoside analogs are featured with high antiviral potency and favorable pharmacokinetics parameters. A nucleoside analog, 6-azauridine, has been demonstrated to be a broad antiviral agent, and therefore, this compound can be potentially used in the treatment of 2019-nCoA. As a long-term expert in the field of immunology, Creative Biolabs offers high-quality validation service of 6-azauridine for the treatment of SARS-CoV-2.